Behavioral and Psychological Symptoms in Alzheimer's Disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Li, Xiao Ling ^a   Hu, Nan ^a   Tan, Meng Shan ^b   Yu, Jin Tai ^a   Tan, Lan ^a,b  

^a QINGDAO UNIVERSITY   (China)

^b OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRESSION; AGITATION; ALZHEIMER DISEASE; APATHY; BEHAVIOR DISORDER; DEPRESSION; HUMAN; MENTAL DISEASE; PSYCHOSIS; REVIEW; SYMPTOMATOLOGY; BEHAVIOR; BIOLOGICAL MODEL; EMOTION; PSYCHOLOGY;

ALZHEIMER DISEASE; BEHAVIOR; EMOTIONS; HUMANS; MODELS, BIOLOGICAL;

EID: 84923572419     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/927804     Document Type: Review

References (110)

1. Y. E. Geda, L. S. Schneider, L. N. Gitlin et al., "Neuropsychiatric symptoms in Alzheimers disease: Past progress and anticipation of the future," Alzheimers & Dementia, vol. 9, no. 5, pp. 602-608, 2013.
2. C. G. Lyketsos, M. C. Carrillo, J. M. Ryan et al., "Neuropsychiatric symptoms in Alzheimers disease," Alzheimers & Dementia, vol. 7, no. 5, pp. 532-539, 2011.
3. D. E. Barnes, K. Yaffe, A. L. Byers, M. McCormick, C. Schaefer, and R. A. Whitmer, "Midlife vs late-life depressive symptoms and risk of dementia: Differential effects for Alzheimer disease and vascular dementia," Archives of General Psychiatry, vol. 69, no. 5, pp. 493-498, 2012.
4. B. J. Gilbert, "The role of amyloid β in the pathogenesis of Alzheimers disease," Journal of Clinical Pathology, vol. 66, no. 5, pp. 362-366, 2013.
5. N. N. Nalivaeva and A. J. Turner, "The amyloid precursor protein: A biochemical enigma in brain development, function and disease," FEBS Letters, vol. 587, no. 13, pp. 2046-2054, 2013.
6. C. Liu, T. Kanekiyo, H. Xu, and G. Bu, "Apolipoprotein e and Alzheimer disease: Risk, mechanisms and therapy," Nature Reviews Neurology, vol. 9, no. 2, pp. 106-118, 2013.
7. C. Reitz, "Dyslipidemia and the risk of Alzheimers disease," Current Atherosclerosis Reports, vol. 15, no. 3, p. 307, 2013.
8. Y. Duan, S. Dong, F. Gu, Y. Hu, and Z. Zhao, "Advances in the pathogenesis of Alzheimers disease: Focusing on tau-mediated neurodegeneration," Translational Neurodegeneration, vol. 1, no. 1, p. 24, 2012.
9. V. H. Cornejo and C. Hetz, "The unfolded protein response in Alzheimers disease," Seminars in Immunopathology, vol. 35, no. 3, pp. 277-292, 2013.
10. R. J. Kelleher and R. L. Soiza, "Evidence of endothelial dysfunction in the development of Alzheimers disease: Is Alzheimers a vascular disorder? The American Journal of Cardiovascular Disease, vol. 3, no. 4, pp. 197-226, 2013.
11. G. L. Caldeira, I. L. Ferreira, and A. C. Rego, "Impaired transcription in Alzheimers disease: Key role in mitochondrial dysfunction and oxidative stress," Journal of AlzheimersDisease, vol. 34, no. 1, pp. 115-131, 2013.
12. A. M. Swomley, S. Forster, J. T. Keeney et al., "Abeta, oxidative stress in Alzheimer disease: Evidence based on proteomics studies," Biochimica et BiophysicaActa, vol. 1842,no. 8, pp. 1248-1257, 2013.
13. K. Sopova, K. Gatsiou, K. Stellos, and C. Laske, "Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimers disease: From pathophysiology to novel treatment strategies," Current Alzheimer Research, vol. 11, no. 1, pp. 27-39, 2014.
14. G. Marwarha and O. Ghribi, "Leptin signaling and Alzheimers disease," The American Journal of Neurodegenerative Disease, vol. 1, no. 3, pp. 245-265, 2012.
15. B. Lipinski and E. Pretorius, "The role of iron-induced fibrin in the pathogenesis of Alzheimers disease and the protective role of magnesium," Frontiers in Human Neuroscience, vol. 7, article 735, 2013.
16. V. K. Ramanan and A. J. Saykin, "Pathways to neurodegeneration: Mechanistic insights from GWAS in Alzheimers disease, Parkinsons disease, and related disorders," The American Journal of Neurodegenerative Disease, vol. 2, no. 3, pp. 145-175, 2013.
17. M. E. Peters, P. B. Rosenberg, M. Steinberg et al., "Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: The cache county study," The American Journal of Geriatric Psychiatry, vol. 21, no. 11, pp. 1116-1124, 2013.
18. B. S. Diniz, M. A. Butters, S. M. Albert, M. A. Dew, and C. F. Reynolds III, "Late-life depression and risk of vascular dementia and Alzheimers disease: Systematic review and meta-analysis of community-based cohort studies," The British Journal of Psychiatry, vol. 202, no. 5, pp. 329-335, 2013.
19. Y. Namekawa, H. Baba, H. Maeshima et al., "Heterogeneity of elderly depression: Increased risk ofAlzheimers disease and Aβ protein metabolism," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 43, pp. 203-208, 2013.
20. L. B. Zahodne, K. Ornstein, S. Cosentino, D. P. Devanand , and Y. Stern, "Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/ aggression," The American Journal of Geriatric Psychiatry, 2013.
21. J. Vilalta-Franch, S. López-Pousa, L. Calvó-Perxas, and J. Garre- Olmo, "Psychosis of Alzheimer disease: Prevalence, incidence, persistence, risk factors, and mortality," The American Journal of Geriatric Psychiatry, vol. 21, no. 11, pp. 1135-1143, 2013.
22. C. Rosén, O. Hansson, K. Blennow, and H. Zetterberg, "Fluid biomarkers in Alzheimers disease-current concepts," Molecular Neurodegeneration, vol. 8, no. 1, article 20, 2013.
23. M. Benoit, G. Berrut, J. Doussaint et al., "Apathy and depression in mild Alzheimers disease: A cross-sectional study using diagnostic criteria," Journal of Alzheimers Disease, vol. 31, no. 2, pp. 325-334, 2012.
24. Y. T. Kwak, Y. Yang, S. J. Pyo, and M. S. Koo, "Clinical characteristics according to depression screening tools in patients with Alzheimers disease: View fromself, caregiver-reported and drug-intervention pattern," Geriatrics & Gerontology International, 2013.
25. B. Borroni, S. Archetti, C. Costanzi et al., "Role of BDNF Val66Met functional polymorphism in Alzheimers diseaserelated depression," Neurobiology of Aging, vol. 30, no. 9, pp. 1406-1412, 2009.
26. S. Usman, H. R. Chaudhary, A. Asif, and M. I. Yahya, "Severity and risk factors of depression in Alzheimers disease," Journal of the College of Physicians and Surgeons Pakistan, vol. 20, no. 5, pp. 327-330, 2010.
27. C. Arbus, V. Gardette, C. E. Cantet et al., "Incidence and predictive factors of depressive symptoms in Alzheimers disease: The REAL.FR study," Journal of Nutrition, Health and Aging, vol. 15, no. 8, pp. 609-617, 2011.
28. S. Van der Mussele, K. Bekelaar,N. Le Bastard et al., "Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimers disease," International Journal of Geriatric Psychiatry, vol. 28, no. 9, pp. 947-958, 2013.
29. C. Holmes, M. Arranz, D. Collier, J. Powell, and S. Lovestone, "Depression in Alzheimers disease: The effect of serotonin receptor gene variation," The American Journal of Medical Genetics-Neuropsychiatric Genetics, vol. 119, no. 1, pp. 40-43, 2003.
30. M. K. P. Lai, S.W. Tsang, M. M. Esiri, P. T. Francis, P. T. Wong, and C. P. Chen, "Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimers disease," Psychopharmacology, vol. 213, no. 2-3, pp. 431-439, 2011.
31. A. L. Pritchard, J. Harris, C.W. Pritchard et al., "Role of 5HT2A and 5HT2C polymorphisms in behavioural and psychological symptoms of Alzheimers disease," Neurobiology of Aging, vol. 29, no. 3, pp. 341-347, 2008.
32. A. L. Pritchard, C. W. Pritchard, P. Bentham, and C. L. Lendon, "Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients,"Dementia and Geriatric CognitiveDisorders, vol. 24, no. 3, pp. 201-206, 2007.
33. A. J. Thomas, M. Hendriksen, M. Piggott et al., "A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimers disease with and without depression," Neuropathology and Applied Neurobiology, vol. 32, no. 3, pp. 296-303, 2006.
34. A. P. Cerri, B. Arosio, C. Viazzoli, R. Confalonieri, F. Teruzzi, and G. Annoni, "-308(G/A) TNF-alpha gene polymorphism and risk of depression late in the life," Archives of Gerontology and Geriatrics, vol. 49, supplement 1, pp. 29-34, 2009.
35. C.Y. Liu, C. J. Hong, T. Y. Liu et al., "Lack of associationbetween the apolipoprotein E genotype and depression in Alzheimers disease," Journal of Geriatric Psychiatry and Neurology, vol. 15, no. 1, pp. 20-23, 2002.
36. I. Blasko, G. Kemmler, S. Jungwirth et al., "Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease," The American Journal of Geriatric Psychiatry, vol. 18, no. 11, pp. 973-982, 2010.
37. K. L. Lanctôt, N. Herrmann, L. Rothenburg, and G. Eryavec, "Behavioral correlates of GABAergic disruption in Alzheimers disease," International Psychogeriatrics, vol. 19, no. 1, pp. 151-158, 2007.
38. K. Kataoka, H. Hashimoto, J. Kawabe et al., "Frontal hypoperfusion in depressed patients with dementia of Alzheimer type demonstrated on 3DSRT,"Psychiatryand Clinical Neurosciences, vol. 64, no. 3, pp. 293-298, 2010.
39. V. A. Holthoff, B. Beuthien-Baumann, E. Kalbe et al., "Regional cerebral metabolism in early Alzheimers disease with clinically significant apathy or depression," Biological Psychiatry, vol. 57, no. 4, pp. 412-421, 2005.
40. S. Terada, E. Oshima, S. Sato et al., "Depressive symptoms and regional cerebral blood flow in Alzheimers disease," Psychiatry Research, vol. 221, no. 1, pp. 86-91, 2014.
41. C. F. Tsai, C. W. Hung, J. F. Lirng, S. J. Wang, and J. L. Fuh, "Differences in brainmetabolism associated with agitation and depression in Alzheimers disease," East Asian Archives of Psychiatry, vol. 23, no. 3, pp. 86-90, 2013.
42. A.V.Lebedev,M.K. Beyer,F. Fritze, E. Westman, C. Ballard, and D. Aarsland , "Cortical changes associated with depression and antidepressant use in Alzheimer and Lewy body dementia: An MRI surface-basedmorphometric study,"TheAmerican Journal of Geriatric Psychiatry, vol. 22, no. 1, pp. 4-13, 2014.
43. J. H. Son, D. H. Han, K. J. Min, and B. S. Kee, "Correlation between gray matter volume in the temporal lobe and depressive symptoms in patients with Alzheimers disease," Neuroscience Letters, vol. 548, pp. 15-20, 2013.
44. G. J. Lee, P. H. Lu, X. Hua et al., "Depressive symptoms in mild cognitive impairment predict greater atrophy in alzheimers disease-related regions," Biological Psychiatry, vol. 71, no. 9, pp. 814-821, 2012.
45. J. A. Brommelhoff, B. M. Spann, J. L. Go, W. J. MacK, and M. Gatz, "Striatal hypodensities, not white matter hypodensities on CT, Are Associated with Late-Onset Depression in Alzheimers Disease," Journal of Aging Research, vol. 2011, Article ID 187219, 11 pages, 2011.
46. Y.-Y. Chou, N. Leporé, P. Saharan et al., "Ventricular maps in 804 ADNI subjects: Correlations with CSF biomarkers and clinical decline," Neurobiology of Aging, vol. 31, no. 8, pp. 1386-1400, 2010.
47. J. Mintzer and C. ONeill, "Depression in Alzheimers disease: Consequence or contributing factor? Expert Review of Neurotherapeutics, vol. 11, no. 11, pp. 1501-1503, 2011.
48. S. Arlt, C. Demiralay, B.Tharun et al., "Genetic risk factors for depression in Alzheimers disease patients," Current Alzheimer Research, vol. 10, no. 1, pp. 72-81, 2013.
49. S. Porcelli, R. Salfi, A. Politis et al., "Association between Sirtuin 2 gene rs10410544 polymorphism and depression inAlzheimers disease in two independent European samples," Journal of Neural Transmission, vol. 120, no. 12, pp. 1709-1715, 2013.
50. L. Zhang, Y. Fang, Z. Zeng et al., "BDNF gene polymorphisms are associated with Alzheimers disease-related depression and antidepressant response," Journal of Alzheimers Disease, vol. 26, no. 3, pp. 523-530, 2011.
51. F. Caraci, P. Bosco, M. Signorelli et al., "The CC genotype of transforming growth factor-β1 increases the risk of lateonset Alzheimers disease and is associated with AD-related depression," European Neuropsychopharmacology, vol. 22, no. 4, pp. 281-289, 2012.
52. L. Delano-Wood, W. S. Houston, J. A. Emond et al., "APOE genotype predicts depression in women with Alzheimers disease: A retrospective study," International Journal of Geriatric Psychiatry, vol. 23, no. 6, pp. 632-636, 2008.
53. A. Michels, M. Multhammer, M. Zintl, M. C. Mendoza, and H. Klünemann, "Association of apolipoprotein E 4 (ApoE 4) homozygosity with psychiatric behavioral symptoms," Journal of Alzheimers Disease, vol. 28, no. 1, pp. 25-32, 2012.
54. G. Spalletta, C. Caltagirone, P. Girardi, W. Gianni, A. R. Casini, and K. Palmer, "The role of persistent and incident major depression on rate of cognitive deterioration in newly diagnosed Alzheimers disease patients," Psychiatry Research, vol. 198, no. 2, pp. 263-268, 2012.
55. K. Palmer, F. Di Iulio, A. E. Varsi et al., "Neuropsychiatric predictors of progression from amnestic-Mild cognitive impairment to Alzheimers disease: The role of depression and apathy," Journal of Alzheimers Disease, vol. 20, no. 1, pp. 175-183, 2010.
56. D. R. Royall and R. F. Palmer, "Alzheimers disease pathology does notmediate the association between depressive symptoms and subsequent cognitive decline," Alzheimers and Dementia, vol. 9, no. 3, pp. 318-325, 2013.
57. N. Mossaheb, S. Zehetmayer, S. Jungwirth et al., "Are specific symptoms of depression predictive of Alzheimers dementia? Journal of Clinical Psychiatry, vol. 73, no. 7, pp. 1009-1015, 2012.
58. H. Lenoir, C. Dufouil, S. Auriacombe et al., "Depression history, depressive symptoms, and incident dementia: The 3C study," Journal of Alzheimers Disease, vol. 26, no. 1, pp. 27-38, 2011.
59. C. Even and D. Weintraub, "Case for and against specificity of depression in Alzheimers disease," Psychiatry and Clinical Neurosciences, vol. 64, no. 4, pp. 358-366, 2010.
60. S. Aznar and G. M. Knudsen, "Depression and alzheimers disease: Is stress the initiating factor in a common neuropathological cascade? Journal of Alzheimers Disease, vol. 23, no. 2, pp. 177-193, 2011.
61. F. Caraci, A. Copani, F. Nicoletti, and F. Drago, "Depression and Alzheimers disease: Neurobiological links and common pharmacological targets," European Journal of Pharmacology, vol. 626, no. 1, pp. 64-71, 2010.
62. P. J. Modrego, "Depression in Alzheimers disease. Pathophysiology, diagnosis, and treatment," Journal of Alzheimers Disease, vol. 21, no. 4, pp. 1077-1087, 2010.
63. A. S. Sierksma, D. L. van den Hove, H. W. Steinbusch, and J. Prickaerts, "Major depression, cognitive dysfunction and Alzheimers disease: Is there a link? European Journal of Pharmacology, vol. 626, no. 1, pp. 72-82, 2010.
64. S. Wuwongse, R. C. Chang, and A. C. K. Law, "The putative neurodegenerative links between depression and Alzheimers disease," Progress in Neurobiology, vol. 91, no. 4, pp. 362-375, 2010.
65. M. Ota,N. Sato, Y. Nakata, K. Arima, and M. Uno, "Relationship between apathy and diffusion tensor imaging metrics of the brain in Alzheimers disease," International Journal of Geriatric Psychiatry, vol. 27, no. 7, pp. 722-726, 2012.
66. D. Grossi, G. Santangelo, A. M. Barbarulo et al., "Apathy and related executive syndromes in dementia associated with Parkinsons disease and in Alzheimers disease," Behavioural Neurology, vol. 27, no. 4, pp. 515-522, 2013.
67. S. Nakaaki, Y. Murata, J. Sato et al., "Association between apathy/depression and executive function in patients with Alzheimers disease," International Psychogeriatrics, vol. 20, no. 5, pp. 964-975, 2008.
68. T. Mori, H. Shimada, H. Shinotoh et al., "Apathy correlates with prefrontal amyloid beta deposition in Alzheimers disease," Journal of Neurology, Neurosurgery & Psychiatry, vol. 85, no. 4, pp. 449-455, 2014.
69. C. Hahn, H. Lim, W. Y. Won, K. J. Ahn, W. Jung, and C. U. Lee, "Apathy and white matter integrity in Alzheimers Disease: A whole brain analysis with tract-based spatial statistics," PLoS ONE, vol. 8, no. 1,Article ID e53493, 2013.
70. N. J. Donovan, L. P. Wadsworth, N. Lorius et al., "Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum," American Journal of Geriatric Psychiatry, 2013.
71. M. Flirski, M. Sieruta, E. Golańska, I. K?oszewska, P. P. Liberski, and T. Sobów, "PRND 3′UTR polymorphismmay be associated with behavioral disturbances in Alzheimer disease," Prion, vol. 6, no. 1, pp. 73-80, 2012.
72. E. Richard, B. Schmand , P. Eikelenboom et al., "Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimers disease in non-depressed subjects for the Alzheimers disease neuroimaging initiative," Dementia and Geriatric Cognitive Disorders, vol. 33, no. 2-3, pp. 204-209, 2012.
73. S. Gonfrier, S. and rieu, D. Renaud, B. Vellas, and P. Robert, "Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort," Journal of Nutrition, Health and Aging, vol. 16, no. 2, pp. 134-137, 2012.
74. L. Bidzan, M. Bidzan, and M. Pachalska, "Aggressive and impulsive behavior in Alzheimers disease and progression of dementia," Medical Science Monitor, vol. 18, no. 3, pp. CR182-CR189, 2012.
75. T. Kitamura, M. Kitamura, S. Hino, N. Tanaka, and K. Kurata, "Gender differences in clinical manifestations and outcomes among hospitalized patients with behavioral and psychological symptoms of dementia," Journal of Clinical Psychiatry, vol. 73, no. 12, pp. 1548-1554, 2012.
76. D. L. Sukonick, B. G. Pollock, R. A. Sweet et al., "The 5-HTTPR?S/?L polymorphism and aggressive behavior in Alzheimer disease," Archives of Neurology, vol. 58, no. 9, pp. 1425-1428, 2001.
77. D. Craig,D. J. Hart, R. Carson, S. P. McIlroy, and A. P. Passmore, "Allelic variation at the A218C tryptophan hydroxylase polymorphism influences agitation and aggression in Alzheimers disease," Neuroscience Letters, vol. 363, no. 3, pp. 199-202, 2004.
78. M. Garcia-Alloza, W. D. Hirst, C. P. L. Chen, B. Lasheras, P. T. Francis, and M. J. Ramírez, "Differential involvement of 5- HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimers disease," Neuropsychopharmacology, vol. 29, no. 2, pp. 410-416, 2004.
79. M. K. P. Lai, S. W. Y. Tsang, P. T. Francis et al., "Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease," Brain Research, vol. 974, no. 1-2, pp. 82-87, 2003.
80. K. L. Lanctôt, N. Herrmann, G. Eryavec, R. van Reekum, K. Reed, and C. A. Naranjo, "Central serotonergic activity is related to the aggressive behaviors of Alzheimers disease," Neuropsychopharmacology, vol. 27, no. 4, pp. 646-654, 2002.
81. R. A. Sweet, B. G. Pollock, D. L. Sukonick et al., "The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease," International Psychogeriatrics, vol. 13, no. 4, pp. 401-409, 2001.
82. R. A. Sweet, V. L. Nimgaonkar, M. L. Kamboh, O. L. Lopez, F. Zhang, and S. T. Dekosky, "Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease," Archives of Neurology, vol. 55, no. 10, pp. 1335-1340, 1998.
83. C. Holmes, H. Smith, R. Gand erton et al., "Psychosis and aggression in Alzheimers disease: The effect of dopamine receptor gene variation," Journal of Neurology Neurosurgery and Psychiatry, vol. 71, no. 6, pp. 777-779, 2001.
84. N. Gormley, M. R. Rizwan, and S. Lovestone, "Clinical predictors of aggressive behaviour in Alzheimers disease," International Journal of Geriatric Psychiatry, vol. 13, no. 2, pp. 109-115, 1998.
85. D. W. Gilley, R. S. Wilson, L. A. Beckett, and D. A. Evans, "Psychotic symptoms and physically aggressive behavior in Alzheimers disease," Journal of the American Geriatrics Society, vol. 45, no. 9, pp. 1074-1079, 1997.
86. A. Eustace, N. Kidd, E. Greene et al., "Verbal aggression in Alzheimers disease. Clinical, functional and neuropsychological correlates," International Journal of Geriatric Psychiatry, vol. 16, no. 9, pp. 858-861, 2001.
87. T. Nagata, N. Kobayashi, S. Shinagawa, H. Yamada, K. Kondo, and K. Nakayama, "Plasma BDNF levels are correlated with aggressiveness in patients with amnestic mild cognitive impairment or Alzheimer disease," Journal of Neural Transmission, vol. 121, no. 4, pp. 433-441, 2013.
88. K. L. Matthews, C. P. L. Chen, M. M. Esiri, J. Keene, S. L. Minger, and P. T. Francis, "Noradrenergic changes, aggressive behavior, and cognition in patients with dementia," Biological Psychiatry, vol. 51, no. 5, pp. 407-416, 2002.
89. N. Herrmann, K. L. Lanctôt, G. Eryavec, R. van Reekum, and L. R. Khan, "Growth hormone response to clonidine predicts aggression in Alzheimers disease," Psychoneuroendocrinology, vol. 29, no. 9, pp. 1192-1197, 2004.
90. P. T. Trzepacz, P. Yu, P. K. Bhamidipati et al., "Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimers disease," Alzheimers and Dementia, vol. 9, no. 5, Supplement, pp. S95.e1-S104.e1, 2013.
91. S. Guadagna, M. M. Esiri, R. J. Williams, and P. T. Francis, "Tau phosphorylation in human brain: Relationship to behavioral disturbance in dementia," Neurobiology of Aging, vol. 33, no. 12, pp. 2798-2806, 2012.
92. K. L. Lanctôt, N. Herrmann, N. K. Nadkarni, F. S. Leibovitch, C. B. Caldwell, and S. E. Black, "Medial temporal hypoperfusion and aggression inAlzheimer disease," Archives of Neurology, vol. 61, no. 11, pp. 1731-1737, 2004.
93. D. Craig, D. J. Hart, K. McCool, S. P. McIlroy, and A. P. Passmore, "Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimers disease," Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 9, pp. 1327-1330, 2004.
94. C. Ballard and A. Corbett, "Agitation and aggression in people with Alzheimers disease," CurrentOpinion in Psychiatry, vol. 26, no. 3, pp. 252-259, 2013.
95. P. A. Wilkosz, H. J. Seltman, B. Devlin et al., "Trajectories of cognitive decline in Alzheimers disease," International Psychogeriatrics, vol. 22, no. 2, pp. 281-290, 2010.
96. B. Creese, C. Ballard, and E. Jones, "Cognitive impairment in studies of 5HTTLPR and psychosis in alzheimers disease: A systematic review," Dementia and Geriatric Cognitive Disorders, vol. 35, no. 3-4, pp. 155-164, 2013.
97. D.W. Gilley, J. L. Bienias, R. S. Wilson,D. A. Bennett, T. L. Beck, and D. A. Evans, "Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimers disease," Psychological Medicine, vol. 34, no. 6, pp. 1129-1135, 2004.
98. J. Koppel, S. Sunday, J. Buthorn, T. Goldberg, P. Davies, and B. Greenwald, "Elevated CSF Tau is associated with psychosis in Alzheimers disease," The American Journal of Psychiatry, vol. 170, no. 10, pp. 1212-1213, 2013.
99. P. S. Murray, C. M. Kirkwood, M. C. Gray et al., "Hyperphosphorylated Tau is elevated in Alzheimers disease with psychosis," Journal of Alzheimers Disease, vol. 39,no. 4, pp. 759-773, 2014.
100. K. F. Zdanys, T. G. Kleiman, M. G. MacAvoy et al., "Apolipoprotein E e4 allele increases risk for psychotic symptoms in Alzheimers disease," Neuropsychopharmacology, vol. 32, no. 1, pp. 171-179, 2007.
101. D. L. Sultzer, L. P. Leskin, R. J. Melrose et al., "Neurobiology of delusions, memory, and insight in alzheimer disease," The American Journal of Geriatric Psychiatry, 2013.
102. J. Koppel, S. Sunday, T. E. Goldberg, P. Davies, E. Christen, and B. S. Greenwald, "Psychosis in Alzheimers disease is associated with frontal metabolic impairment and accelerated decline in working memory: Findings from the Alzheimers disease neuroimaging initiative," The American Journal of Geriatric Psychiatry, vol. 22, no. 7, pp. 698-707, 2013.
103. J. Koppel, T. E. Goldberg, M. L. Gordon et al., "Relationships between behavioral syndromes and cognitive domains in alzheimer disease: The impact of mood and psychosis," The American Journal of Geriatric Psychiatry, vol. 20,no. 11,pp. 994-1000, 2012.
104. M. S. Rafii, C. S. Taylor, H. T. Kim et al., "Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimers disease," American Journal of Alzheimers Disease & Other Dementias, vol. 29, no. 2, pp. 159-165, 2014.
105. K. Nomura, H. Kazui, T. Wada et al., "Classification of delusions in Alzheimers disease and their neural correlates," Psychogeriatrics, vol. 12, no. 3, pp. 200-210, 2012.
106. Z. Ismail,M. Nguyen, C. E. Fischer, T. A. Schweizer, and B. H. Mulsant, "Neuroimaging of delusions in Alzheimers disease," Psychiatry Research-Neuroimaging, vol. 202, no. 2, pp. 89-95, 2012.
107. S. J. Reeves, R. L. Gould, J. F. Powell, and R. J. Howard, "Origins of delusions in Alzheimers disease," Neuroscience & Biobehavioral Reviews, vol. 36, no. 10, pp. 2274-2287, 2012.
108. Y. T. Kwak,Y. Yang, S. Kwak, and M. Koo, "Delusions of Korean patients with Alzheimers disease: Study of drug-na?ve patients," Geriatrics and Gerontology International, vol. 13, no. 2, pp. 307-313, 2013.
109. P. S. Murray, C. M. Kirkwood, M. C. Gray et al., "β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis," Neurobiology of Aging, vol. 33, no. 12, pp. 2807-2816, 2012.
110. E. Di Maria, C. Bonvicini, C. Bonomini, A. Alberici, O. Zanetti, and M. Gennarelli, "Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimers disease," Journal of Alzheimers Disease, vol. 18, no. 4, pp. 953-960, 2009.